Kairos Pharma Ltd.

11/11/2025

This , Kairos stands with patients, families, and researchers working toward better outcomes and a brighter future for men’s health.

is advancing innovative science and next-generation to transform the future of treatment of .

Learn more about how is driving progress: kairospharma.com

11/06/2025

's CEO, John Yu, M.D, shared insights with AlphaStreet on how is developing targeted therapeutics designed to extend the effectiveness of existing and improve patient outcomes as it advances its lead program, ENV105.

Read the full interview:

Kairos Pharma, Ltd. (NYSE: KAPA) is a biopharma company developing a pipeline of targeted therapies for cancer patients with high unmet medical needs. In an interview with AlphaStreet, Kairo Pharma's chief executive officer, Dr. John Yu, shared valuable insights into the company's approach to cancer...

11/04/2025

provides a shareholder update highlighting 2025 progress and 2026 plans.

announced positive interim Phase 2 results for ENV105 + apalutamide in advanced , showing 86% clinical benefit and no dose-limiting toxicities or unexpected adverse events.

Additional 2025 highlights include data at major oncology meetings, new Department of Defense funding, and peer-reviewed publications on the role of CD105 in cancer resistance.

Looking ahead, will advance , publish data, pursue partnerships, and progress investigational candidates.

Read the full release: bit.ly/4hDG6XU

10/31/2025

We’re excited to share that Technology Networks is hosting an interactive AMA with 's Chief Scientific Officer, Neil Bhowmick, PhD.

As a leading cancer biologist and translational researcher, Dr. Bhowmick will share his insights on cutting-edge strategies reshaping .

The conversation will be live this Friday (Oct 31) at 12 PM ET.

Learn more and register: https://bit.ly/3Wan8hW

10/23/2025

is pioneering a new approach to focused on overcoming drug resistance.

By developing resistance reversal therapeutics like , Kairos aims to improve the effectiveness of existing therapies and give patients more time.

Read the full interview in Invezz with CEO, John Yu, M.D:

J

10/20/2025

presents on the positive interim efficacy data from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant ( ) at the annual ESMO - European Society for Medical Oncology's 2025 European Congress.

The interim efficacy analysis highlights potential value of combination therapy.

Read the full release here: bit.ly/4oxy716

10/17/2025

This year, more than 313,000 men in the U.S. are expected to be diagnosed with , with over 35,000 deaths projected, according to the American Cancer Society.

is advancing innovative science to transform the future of treatment and improve outcomes for patients facing this disease.

Learn more about how is driving progress: kairospharma.com

10/09/2025

The 2025 Nobel Prize winners in Physiology or Medicine were honored for discoveries in immune tolerance, highlighting the role of regulatory T cells (Tregs) in cancer’s ability to evade the immune system.

is advancing this frontier with KROS-101, our GITR ligand agonist that expands cytotoxic T cells while inhibiting Tregs to target cancer cells and reverse immune suppression, reprogramming the tumor microenvironment to strengthen the body’s natural anti-cancer defenses.

's commitment to translating this Nobel-recognized science into transformative therapies underscores our dedication to improving outcomes for cancer patients worldwide.

Learn more about the 2025 winners and the discoveries behind regulatory T cells:

The Nobel Prize in Physiology or Medicine 2025 was awarded jointly to Mary E. Brunkow, Frederick J. Ramsdell and Shimon Sakaguchi "for their discoveries concerning peripheral immune tolerance"

10/01/2025

’s CEO & Chairman, John Yu, M.D., was featured in an article from on the keys to making rare disease drug development sustainable.

Check out both Dr. Yu and other experts comments here: https://bit.ly/4pIe7u1